Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2848878
Reference Type
Journal Article
Title
Effects of Low-Level Laser Therapy on the Serum TGF-beta 1 Concentrations in Individuals with Autoimmune Thyroiditis
Author(s)
Hoefling, DB; Chavantes, MC; Acencio, MMP; Cerri, GG; Marui, S; Yoshimura, EM; Chammas, MC
Year
2014
Is Peer Reviewed?
1
Journal
Photomedicine and Laser Surgery
ISSN:
1549-5418
EISSN:
1557-8550
Volume
32
Issue
8
Page Numbers
444-449
PMID
25101534
DOI
10.1089/pho.2014.3716
Web of Science Id
WOS:000340526100004
Abstract
Objective: The objective of this study was to evaluate the serum concentration of transforming growth factor-beta 1 (TGF-beta 1) after low-level laser therapy (LLLT) in patients with hypothyroidism resulting from chronic autoimmune thyroiditis (CAT). Background data: Certain data indicate that LLLT is effective in patients with hypothyroidism caused by CAT; however, the mechanisms of action of LLLT in thyroid tissue are unknown. Cytokines could play a role in the response to LLLT. Methods: A randomized, placebo-controlled trial included 43 patients with a history of levothyroxine therapy for CAT-induced hypothyroidism. The patients were randomly assigned to receive either 10 sessions of LLLT (830 nm, 50 mW output power, and 707 J/cm(2) fluence; L group, n = 23) or 10 sessions of a placebo treatment (P group, n = 20) twice a week. Levothyroxine was maintained at the same dose during the entire study period. TGF-beta 1 was measured both pre-intervention and 30 days post-intervention in both groups. The differences were calculated between the TGF-beta 1 values observed 30 days post-intervention and the pre-intervention TGF-beta 1 values for each group (intragroup). Results: Comparing the differences in TGF-beta 1 levels between the L group (874.9 +/- 541.7 pg/mL) and the P group (-128.4 +/- 832.8 pg/mL) revealed that there was a statistically significant increase in TGF-beta 1 levels 30 days post-intervention in group L compared with the placebo group (p = 0.0379). Conclusions: This finding suggested that the significant increase in serum TGF-beta 1 levels in patients with CAT-induced hypothyroidism was associated with the thyroid LLLT procedure. Future studies of the effect of LLLT on TGF-beta 1 gene expression in thyroid tissue are necessary to confirm these findings.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity